 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"TIGECYCLINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: TIGECYCLINE: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: All-Cause Mortality [0m[31m Mortality Imbalance and Lower Cure [0m
[31mRates in Hospital-Acquired Pneumonia [0m[31m Anaphylaxis [0m[1;31m[[0m[31mWarning and Precautions [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Hepatic Adverse Effects [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Pancreatitis [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[1;31m][0m[31m The most [0m
[31mcommon adverse reactions [0m[1;31m([0m[31mincidence >[0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m are nausea, vomiting, diarrhea, abdominal pain, headache, and increased SGPT. [0m[1;31m([0m[31m [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Apotex at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m706[0m[31m-[0m[1;31m5575[0m[31m [0m
[31mor FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www. TIGECYCLINE: adverse_reactions: da.gov/medwatch [0m[1;31m6.1[0m[31m Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction [0m
[31mrates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, [0m[1;31m2514[0m
[31mpatients were treated with tigecycline for injection. Tigecycline for injection was discontinued due to adverse reactions in [0m[1;31m7[0m[31m% of patients compared to [0m[1;31m6[0m[31m% for all comparators. Table [0m[1;31m1[0m[31m shows the [0m
[31mincidence of adverse reactions through test of cure reported in â‰¥[0m[1;31m2[0m[31m% of patients in these trials. Table [0m[1;31m1[0m[31m. TIGECYCLINE: adverse_reactions: Incidence [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Adverse Reactions Through Test of Cure [0m
[31mReported in â‰¥ [0m[1;31m2[0m[31m% of Patients Treated in Clinical Studies Body System Tigecycline for injection Comparators a Adverse Reactions [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2514[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2307[0m[1;31m)[0m[31m a Vancomycin/Aztreonam, Imipenem/Cilastatin, [0m
[31mLevofloxacin, Linezolid. b LFT abnormalities in tigecycline for injection-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which [0m
[31moccurred more often on therapy.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: adverse_reactions: In patients treated for complicated skin and skin structure infections [0m[1;31m([0m[31mcSSSI[0m[1;31m)[0m[31m, nausea incidence was [0m[1;31m35[0m[31m% for tigecycline for injection and [0m[1;31m9[0m[31m% for [0m
[31mvancomycin/aztreonam; vomiting incidence was [0m[1;31m20[0m[31m% for tigecycline for injection and [0m[1;31m4[0m[31m% for vancomycin/aztreonam. In patients treated for complicated intra-abdominal infections [0m[1;31m([0m[31mcIAI[0m[1;31m)[0m[31m, nausea incidence [0m
[31mwas [0m[1;31m25[0m[31m% for tigecycline for injection and [0m[1;31m21[0m[31m% for imipenem/cilastatin; vomiting incidence was [0m[1;31m20[0m[31m% for tigecycline for injection and [0m[1;31m15[0m[31m% for imipenem/cilastatin. TIGECYCLINE: adverse_reactions: In [0m
[31mpatients treated for community-acquired bacterial pneumonia [0m[1;31m([0m[31mCABP[0m[1;31m)[0m[31m, nausea incidence was [0m[1;31m24[0m[31m% for tigecycline for injection and [0m[1;31m8[0m[31m% for levofloxacin; vomiting incidence was [0m[1;31m16[0m[31m% for tigecycline for [0m
[31minjection and [0m[1;31m6[0m[31m% for levofloxacin. Discontinuation from tigecycline for injection was most frequently associated with nausea [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m and vomiting [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m. For comparators, discontinuation was most [0m
[31mfrequently associated with nausea [0m[1;31m([0m[31m<[0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m. TIGECYCLINE: adverse_reactions: The following adverse reactions were reported [0m[1;31m([0m[31m<[0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m in patients receiving tigecycline for injection in clinical studies: Body [0m
[31mas a Whole : injection site inflammation, injection site pain, injection site reaction, septic shock, allergic reaction, chills, injection site edema, injection site phlebitis Cardiovascular System: [0m
[31mthrombophlebitis Digestive System: anorexia, jaundice, abnormal stools Metabolic/Nutritional System: increased creatinine, hypocalcemia, hypoglycemia Special Senses: taste perversion Hemic and [0m
[31mLymphatic System : prolonged activated partial thromboplastin time [0m[1;31m([0m[31maPTT[0m[1;31m)[0m[31m, prolonged prothrombin time [0m[1;31m([0m[31mPT[0m[1;31m)[0m[31m, eosinophilia, increased international normalized ratio [0m[1;31m([0m[31mINR[0m[1;31m)[0m[31m, thrombocytopenia Skin and [0m
[31mAppendages: pruritus Urogenital System: vaginal moniliasis, vaginitis, leukorrhea [0m[1;31m6[0m[31m. TIGECYCLINE: adverse_reactions: [0m[1;31m2[0m[31m Post-Marketing Experience The following adverse reactions have been identified [0m
[31mduring post-approval use of tigecycline for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their [0m
[31mfrequency or establish causal relationship to drug exposure. anaphylactic reactions acute pancreatitis hepatic cholestasis, and jaundice severe skin reactions, including Stevens-Johnson Syndrome [0m
[31msymptomatic hypoglycemia in patients with and without diabetes mellitus hypofibrinogenemia [0m[1;31m[[0m[31msee Warnings and Precautions [0m[1;31m([0m[1;31m5[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS All-Cause Mortality: A meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials demonstrated an increase in all-cause mortality in [0m
[31mtigecycline for injection-treated patients compared to controls with a risk difference of [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this increase has not been established. An increase was also seen in a [0m
[31mmeta-analysis limited to the approved indications [0m[1;31m[[0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[1;31m][0m[31m. The greatest difference in mortality was seen in tigecycline for injection-treated patients with ventilator-associated [0m
[31mpneumonia. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Anaphylactic Reactions: have been reported with tigecycline for injection and may be life-threatening. Avoid use in patients with known hypersensitivity to tetracyclines. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m.[0m
[31mTIGECYCLINE: warnings_and_cautions: [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m Hepatic Adverse Effects: have been reported with tigecycline for injection. Patients who develop abnormal liver function tests during tigecycline for injection [0m
[31mtherapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Pancreatitis: including fatalities, has been reported [0m
[31mwith tigecycline for injection. If pancreatitis is suspected, then consider stopping tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Monitoring Blood Coagulation Parameters: Hypofibrinogenemia has been reported [0m
[31mwith tigecycline for injection. Monitor blood coagulation parameters, including fibrinogen, at baseline and regularly during treatment with tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m. TIGECYCLINE: [0m
[31mwarnings_and_cautions: [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m Tooth Discoloration and Enamel Hypoplasia: The use of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and childhood to the age of [0m[1;31m8[0m[31m [0m
[31myears[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m and enamel hypoplasia. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m Inhibition of Bone Growth: The use of tigecycline for injection during the second and third [0m
[31mtrimester of pregnancy, infancy, and childhood up to the age of [0m[1;31m8[0m[31m years may cause reversible inhibition of bone growth. [0m[1;31m([0m[31m [0m[1;31m5.8[0m[31m [0m[1;31m)[0m[31m Clostridium difficile associated Diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m: evaluate if diarrhea [0m
[31moccurs. [0m[1;31m([0m[1;31m5.9[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m All-Cause Mortality An increase in all-cause mortality has been observed in a meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials in tigecycline for injection-treated patients versus [0m
[31mcomparator-treated patients.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: The adjusted risk difference for mortality stratified by trial weight was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this mortality difference has not been [0m
[31mestablished. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities. Tigecycline for injection should be reserved for use in situations when [0m
[31malternative treatments are not suitable [0m[31m . [0m[1;31m5.2[0m[31m Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia A trial of patients with hospital acquired, including ventilator-associated, [0m
[31mpneumonia failed to demonstrate the efficacy of tigecycline for injection. TIGECYCLINE: warnings_and_cautions: In this trial, patients were randomized to receive tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg [0m
[31minitially, then [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m or a comparator. In addition, patients were allowed to receive specified adjunctive therapies. The sub-group of patients with ventilator-associated pneumonia who [0m
[31mreceived tigecycline for injection had lower cure rates [0m[1;31m([0m[1;31m47.9[0m[31m% versus [0m[1;31m70.1[0m[31m% for the clinically evaluable population[0m[1;31m)[0m[31m. In this trial, greater mortality was seen in patients with ventilator-associated [0m
[31mpneumonia who received tigecycline for injection [0m[1;31m([0m[1;31m25[0m[31m/[0m[1;31m131[0m[31m [0m[1;31m[[0m[1;31m19.1[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m15[0m[31m/[0m[1;31m122[0m[31m [0m[1;31m[[0m[1;31m12.3[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m [0m[31m . Particularly high mortality was seen among tigecycline for injection-treated [0m
[31mpatients with ventilator-associated pneumonia and bacteremia at baseline [0m[1;31m([0m[1;31m9[0m[31m/[0m[1;31m18[0m[31m [0m[1;31m[[0m[1;31m50.0[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m1[0m[31m/[0m[1;31m13[0m[31m [0m[1;31m[[0m[1;31m7[0m[31m. TIGECYCLINE: warnings_and_cautions: [0m[1;31m7[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m. [0m[1;31m5.3[0m[31m Anaphylactic [0m
[31mReactions Anaphylactic reactions have been reported with nearly all antibacterial agents, including tigecycline for injection, and may be life-threatening. Tigecycline for injection is structurally [0m
[31msimilar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs. [0m[1;31m5.4[0m[31m Hepatic Adverse Effects Increases in [0m
[31mtotal bilirubin concentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been [0m
[31mreported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications. TIGECYCLINE: warnings_and_cautions: Patients who develop abnormal liver [0m
[31mfunction tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. Hepatic dysfunction may occur[0m
[31mafter the drug has been discontinued. [0m[1;31m5.5[0m[31m Pancreatitis Acute pancreatitis, including fatal cases, has occurred in association with tigecycline treatment. The diagnosis of acute pancreatitis should be [0m
[31mconsidered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. Cases have been reported in patients without known risk [0m
[31mfactors for pancreatitis. Patients usually improve after tigecycline discontinuation. Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having [0m
[31mdeveloped pancreatitis [0m[31m . [0m[1;31m5[0m[31m. TIGECYCLINE: warnings_and_cautions: [0m[1;31m6[0m[31m Monitoring of Blood Coagulation Parameters Hypofibrinogenemia has been reported in patients treated with tigecycline for injection [0m[31m .[0m
[31mObtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with tigecycline for injection. [0m[1;31m5.7[0m[31m Tooth Discoloration and Enamel Hypoplasia The[0m
[31muse of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and childhood to the age of [0m[1;31m8[0m[31m years[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m. [0m
[31mThis adverse reaction is more common during long-term use of tetracyclines, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported.         [0m
[31mSOURCE:TIGECYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"TIGECYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does TIGECYCLINE increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"TIGECYCLINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: TIGECYCLINE: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: All-Cause Mortality [0m[31m Mortality Imbalance and Lower Cure [0m
[31mRates in Hospital-Acquired Pneumonia [0m[31m Anaphylaxis [0m[1;31m[[0m[31mWarning and Precautions [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Hepatic Adverse Effects [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Pancreatitis [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[1;31m][0m[31m The most [0m
[31mcommon adverse reactions [0m[1;31m([0m[31mincidence >[0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m are nausea, vomiting, diarrhea, abdominal pain, headache, and increased SGPT. [0m[1;31m([0m[31m [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Apotex at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m706[0m[31m-[0m[1;31m5575[0m[31m [0m
[31mor FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www. TIGECYCLINE: adverse_reactions: da.gov/medwatch [0m[1;31m6.1[0m[31m Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction [0m
[31mrates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, [0m[1;31m2514[0m
[31mpatients were treated with tigecycline for injection. Tigecycline for injection was discontinued due to adverse reactions in [0m[1;31m7[0m[31m% of patients compared to [0m[1;31m6[0m[31m% for all comparators. Table [0m[1;31m1[0m[31m shows the [0m
[31mincidence of adverse reactions through test of cure reported in â‰¥[0m[1;31m2[0m[31m% of patients in these trials. Table [0m[1;31m1[0m[31m. TIGECYCLINE: adverse_reactions: Incidence [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Adverse Reactions Through Test of Cure [0m
[31mReported in â‰¥ [0m[1;31m2[0m[31m% of Patients Treated in Clinical Studies Body System Tigecycline for injection Comparators a Adverse Reactions [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2514[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2307[0m[1;31m)[0m[31m a Vancomycin/Aztreonam, Imipenem/Cilastatin, [0m
[31mLevofloxacin, Linezolid. b LFT abnormalities in tigecycline for injection-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which [0m
[31moccurred more often on therapy.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: adverse_reactions: In patients treated for complicated skin and skin structure infections [0m[1;31m([0m[31mcSSSI[0m[1;31m)[0m[31m, nausea incidence was [0m[1;31m35[0m[31m% for tigecycline for injection and [0m[1;31m9[0m[31m% for [0m
[31mvancomycin/aztreonam; vomiting incidence was [0m[1;31m20[0m[31m% for tigecycline for injection and [0m[1;31m4[0m[31m% for vancomycin/aztreonam. In patients treated for complicated intra-abdominal infections [0m[1;31m([0m[31mcIAI[0m[1;31m)[0m[31m, nausea incidence [0m
[31mwas [0m[1;31m25[0m[31m% for tigecycline for injection and [0m[1;31m21[0m[31m% for imipenem/cilastatin; vomiting incidence was [0m[1;31m20[0m[31m% for tigecycline for injection and [0m[1;31m15[0m[31m% for imipenem/cilastatin. TIGECYCLINE: adverse_reactions: In [0m
[31mpatients treated for community-acquired bacterial pneumonia [0m[1;31m([0m[31mCABP[0m[1;31m)[0m[31m, nausea incidence was [0m[1;31m24[0m[31m% for tigecycline for injection and [0m[1;31m8[0m[31m% for levofloxacin; vomiting incidence was [0m[1;31m16[0m[31m% for tigecycline for [0m
[31minjection and [0m[1;31m6[0m[31m% for levofloxacin. Discontinuation from tigecycline for injection was most frequently associated with nausea [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m and vomiting [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m. For comparators, discontinuation was most [0m
[31mfrequently associated with nausea [0m[1;31m([0m[31m<[0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m. TIGECYCLINE: adverse_reactions: The following adverse reactions were reported [0m[1;31m([0m[31m<[0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m in patients receiving tigecycline for injection in clinical studies: Body [0m
[31mas a Whole : injection site inflammation, injection site pain, injection site reaction, septic shock, allergic reaction, chills, injection site edema, injection site phlebitis Cardiovascular System: [0m
[31mthrombophlebitis Digestive System: anorexia, jaundice, abnormal stools Metabolic/Nutritional System: increased creatinine, hypocalcemia, hypoglycemia Special Senses: taste perversion Hemic and [0m
[31mLymphatic System : prolonged activated partial thromboplastin time [0m[1;31m([0m[31maPTT[0m[1;31m)[0m[31m, prolonged prothrombin time [0m[1;31m([0m[31mPT[0m[1;31m)[0m[31m, eosinophilia, increased international normalized ratio [0m[1;31m([0m[31mINR[0m[1;31m)[0m[31m, thrombocytopenia Skin and [0m
[31mAppendages: pruritus Urogenital System: vaginal moniliasis, vaginitis, leukorrhea [0m[1;31m6[0m[31m. TIGECYCLINE: adverse_reactions: [0m[1;31m2[0m[31m Post-Marketing Experience The following adverse reactions have been identified [0m
[31mduring post-approval use of tigecycline for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their [0m
[31mfrequency or establish causal relationship to drug exposure. anaphylactic reactions acute pancreatitis hepatic cholestasis, and jaundice severe skin reactions, including Stevens-Johnson Syndrome [0m
[31msymptomatic hypoglycemia in patients with and without diabetes mellitus hypofibrinogenemia [0m[1;31m[[0m[31msee Warnings and Precautions [0m[1;31m([0m[1;31m5[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS All-Cause Mortality: A meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials demonstrated an increase in all-cause mortality in [0m
[31mtigecycline for injection-treated patients compared to controls with a risk difference of [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this increase has not been established. An increase was also seen in a [0m
[31mmeta-analysis limited to the approved indications [0m[1;31m[[0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[1;31m][0m[31m. The greatest difference in mortality was seen in tigecycline for injection-treated patients with ventilator-associated [0m
[31mpneumonia. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Anaphylactic Reactions: have been reported with tigecycline for injection and may be life-threatening. Avoid use in patients with known hypersensitivity to tetracyclines. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m.[0m
[31mTIGECYCLINE: warnings_and_cautions: [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m Hepatic Adverse Effects: have been reported with tigecycline for injection. Patients who develop abnormal liver function tests during tigecycline for injection [0m
[31mtherapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Pancreatitis: including fatalities, has been reported [0m
[31mwith tigecycline for injection. If pancreatitis is suspected, then consider stopping tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Monitoring Blood Coagulation Parameters: Hypofibrinogenemia has been reported [0m
[31mwith tigecycline for injection. Monitor blood coagulation parameters, including fibrinogen, at baseline and regularly during treatment with tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m. TIGECYCLINE: [0m
[31mwarnings_and_cautions: [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m Tooth Discoloration and Enamel Hypoplasia: The use of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and childhood to the age of [0m[1;31m8[0m[31m [0m
[31myears[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m and enamel hypoplasia. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m Inhibition of Bone Growth: The use of tigecycline for injection during the second and third [0m
[31mtrimester of pregnancy, infancy, and childhood up to the age of [0m[1;31m8[0m[31m years may cause reversible inhibition of bone growth. [0m[1;31m([0m[31m [0m[1;31m5.8[0m[31m [0m[1;31m)[0m[31m Clostridium difficile associated Diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m: evaluate if diarrhea [0m
[31moccurs. [0m[1;31m([0m[1;31m5.9[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m All-Cause Mortality An increase in all-cause mortality has been observed in a meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials in tigecycline for injection-treated patients versus [0m
[31mcomparator-treated patients.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: The adjusted risk difference for mortality stratified by trial weight was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this mortality difference has not been [0m
[31mestablished. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities. Tigecycline for injection should be reserved for use in situations when [0m
[31malternative treatments are not suitable [0m[31m . [0m[1;31m5.2[0m[31m Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia A trial of patients with hospital acquired, including ventilator-associated, [0m
[31mpneumonia failed to demonstrate the efficacy of tigecycline for injection. TIGECYCLINE: warnings_and_cautions: In this trial, patients were randomized to receive tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg [0m
[31minitially, then [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m or a comparator. In addition, patients were allowed to receive specified adjunctive therapies. The sub-group of patients with ventilator-associated pneumonia who [0m
[31mreceived tigecycline for injection had lower cure rates [0m[1;31m([0m[1;31m47.9[0m[31m% versus [0m[1;31m70.1[0m[31m% for the clinically evaluable population[0m[1;31m)[0m[31m. In this trial, greater mortality was seen in patients with ventilator-associated [0m
[31mpneumonia who received tigecycline for injection [0m[1;31m([0m[1;31m25[0m[31m/[0m[1;31m131[0m[31m [0m[1;31m[[0m[1;31m19.1[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m15[0m[31m/[0m[1;31m122[0m[31m [0m[1;31m[[0m[1;31m12.3[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m [0m[31m . Particularly high mortality was seen among tigecycline for injection-treated [0m
[31mpatients with ventilator-associated pneumonia and bacteremia at baseline [0m[1;31m([0m[1;31m9[0m[31m/[0m[1;31m18[0m[31m [0m[1;31m[[0m[1;31m50.0[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m1[0m[31m/[0m[1;31m13[0m[31m [0m[1;31m[[0m[1;31m7[0m[31m. TIGECYCLINE: warnings_and_cautions: [0m[1;31m7[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m. [0m[1;31m5.3[0m[31m Anaphylactic [0m
[31mReactions Anaphylactic reactions have been reported with nearly all antibacterial agents, including tigecycline for injection, and may be life-threatening. Tigecycline for injection is structurally [0m
[31msimilar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs. [0m[1;31m5.4[0m[31m Hepatic Adverse Effects Increases in [0m
[31mtotal bilirubin concentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been [0m
[31mreported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications. TIGECYCLINE: warnings_and_cautions: Patients who develop abnormal liver [0m
[31mfunction tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. Hepatic dysfunction may occur[0m
[31mafter the drug has been discontinued. [0m[1;31m5.5[0m[31m Pancreatitis Acute pancreatitis, including fatal cases, has occurred in association with tigecycline treatment. The diagnosis of acute pancreatitis should be [0m
[31mconsidered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. Cases have been reported in patients without known risk [0m
[31mfactors for pancreatitis. Patients usually improve after tigecycline discontinuation. Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having [0m
[31mdeveloped pancreatitis [0m[31m . [0m[1;31m5[0m[31m. TIGECYCLINE: warnings_and_cautions: [0m[1;31m6[0m[31m Monitoring of Blood Coagulation Parameters Hypofibrinogenemia has been reported in patients treated with tigecycline for injection [0m[31m .[0m
[31mObtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with tigecycline for injection. [0m[1;31m5.7[0m[31m Tooth Discoloration and Enamel Hypoplasia The[0m
[31muse of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and childhood to the age of [0m[1;31m8[0m[31m years[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m. [0m
[31mThis adverse reaction is more common during long-term use of tetracyclines, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported.         [0m
[31mSOURCE:TIGECYCLINE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the TIGECYCLINE label does not specifically mention angioedema as an adverse reaction. However, anaphylactic reactions, which can include symptoms such as [0m
[32mangioedema, have been reported with tigecycline for injection and may be life-threatening. Patients with known hypersensitivity to tetracyclines should avoid using tigecycline due to the risk of [0m
[32mserious allergic reactions.[0m

[32mSOURCE: TIGECYCLINE label[0m
[32mEXTRACT_START_END: Anaphylactic Reactions: have been reported [0m[32m...[0m[32m to tetracycline-class antibacterial drugs.[0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the TIGECYCLINE label does not [0m
[34mspecifically mention angioedema as an adverse reaction. However, anaphylactic reactions, which can include symptoms such as angioedema, have been reported with tigecycline for injection and may be [0m
[34mlife-threatening. Patients with known hypersensitivity to tetracyclines should avoid using tigecycline due to the risk of serious allergic reactions.[0m

[34mSOURCE: TIGECYCLINE label[0m
[34mEXTRACT_START_END: Anaphylactic Reactions: have been reported [0m[34m...[0m[34m to tetracycline-class antibacterial drugs.[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the TIGECYCLINE label does not specifically mention angioedema as an adverse reaction. However, anaphylactic reactions, which can include symptoms such as angioedema, [0m
[32mhave been reported with tigecycline for injection and may be life-threatening. Patients with known hypersensitivity to tetracyclines should avoid using tigecycline due to the risk of serious allergic [0m
[32mreactions."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for TIGECYCLINE does not specifically list angioedema as an adverse reaction, but anaphylactic reactions, which can include angioedema, have been reported. Therefore, [0m
[32mwhile a direct causal relationship is not established, there is a potential risk of angioedema, especially in patients with known hypersensitivity to tetracyclines."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does TIGECYCLINE increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the TIGECYCLINE label does not specifically mention angioedema as an adverse reaction. However, anaphylactic reactions, which can include symptoms such as angioedema, [0m
[34mhave been reported with tigecycline for injection and may be life-threatening. Patients with known hypersensitivity to tetracyclines should avoid using tigecycline due to the risk of serious allergic [0m
[34mreactions."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for TIGECYCLINE does not specifically list angioedema as an adverse reaction, but anaphylactic reactions, which can include angioedema, have been reported. Therefore, [0m
[34mwhile a direct causal relationship is not established, there is a potential risk of angioedema, especially in patients with known hypersensitivity to tetracyclines."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does TIGECYCLINE increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that the TIGECYCLINE label does not specifically mention angioedema as an adverse reaction. However, anaphylactic reactions, which can include symptoms such as angioedema, have[0m
[31mbeen reported with tigecycline for injection and may be life-threatening. Patients with known hypersensitivity to tetracyclines should avoid using tigecycline due to the risk of serious allergic [0m
[31mreactions.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for TIGECYCLINE does not specifically list angioedema as an adverse reaction, but anaphylactic reactions, which can include angioedema, have been reported. [0m
[31mTherefore, while a direct causal relationship is not established, there is a potential risk of angioedema, especially in patients with known hypersensitivity to tetracyclines.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe FDA label for TIGECYCLINE does not specifically list angioedema as an adverse reaction, but anaphylactic reactions, which can include symptoms such as angioedema, have been reported. Therefore, [0m
[32mwhile a direct causal relationship is not established, there is a potential risk of angioedema, especially in patients with known hypersensitivity to tetracyclines.[0m
